Vision Sensing Acquisition Corp. (VSAC), a Special Purpose Acquisition Company (SPAC), has announced a payment of $51,016.10 to extend its deadline for consummating its initial business combination with Mediforum Co., Ltd. from June 3, 2024, to July 3, 2024. This extension is the second of up to six one-month extensions permitted under VSAC’s amended certificate of incorporation. Mediforum, a leading Korean biotechnology firm, specializes in treatments for Alzheimer’s disease, neuropathic pain, and other conditions. The business combination agreement between VSAC and Mediforum promises to facilitate Mediforum’s anticipated NASDAQ listing, marking it as the first Korean biotech company on the platform. Additionally, several advisory firms are involved in facilitating this transaction, including Norwich Capital Limited and American General Business Association & SME Overseas IPO Capital Group as advisors, and various legal firms providing counsel. The transaction highlights both firms’ plans to finalize this significant merger, pending necessary approvals and regulatory filings.

Biotechnology, Special Purpose Acquisition Companies (SPACs), Healthcare,United States, South Korea